Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 8:25 pm

Competitors of Vivimed Labs Ltd

All Competitor Stocks of Vivimed Labs Ltd

Quarterly Result

Last Updated: March 4, 2025, 2:54 pm

Below is a detailed analysis of the quarterly data for Vivimed Labs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Sales, as of Dec 2024, the value is 36.51 Cr.. The value appears strong and on an upward trend. It has increased from 24.77 Cr. (Sep 2024) to 36.51 Cr., marking an increase of 11.74 Cr..
• For Expenses, as of Dec 2024, the value is 35.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.41 Cr. (Sep 2024) to 35.46 Cr., marking an increase of 10.05 Cr..
• For Operating Profit, as of Dec 2024, the value is 1.05 Cr.. The value appears strong and on an upward trend. It has increased from -0.64 Cr. (Sep 2024) to 1.05 Cr., marking an increase of 1.69 Cr..
• For OPM %, as of Dec 2024, the value is 2.88%. The value appears strong and on an upward trend. It has increased from -2.58% (Sep 2024) to 2.88%, marking an increase of 5.46%.
• For Other Income, as of Dec 2024, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.04 Cr..
• For Interest, as of Dec 2024, the value is 0.48 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.43 Cr. (Sep 2024) to 0.48 Cr., marking an increase of 0.05 Cr..
• For Depreciation, as of Dec 2024, the value is 6.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.10 Cr. (Sep 2024) to 6.62 Cr., marking an increase of 2.52 Cr..
• For Profit before tax, as of Dec 2024, the value is -5.98 Cr.. The value appears to be declining and may need further review. It has decreased from -5.14 Cr. (Sep 2024) to -5.98 Cr., marking a decrease of 0.84 Cr..
• For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
• For Net Profit, as of Dec 2024, the value is -5.98 Cr.. The value appears to be declining and may need further review. It has decreased from -5.14 Cr. (Sep 2024) to -5.98 Cr., marking a decrease of 0.84 Cr..
• For EPS in Rs, as of Dec 2024, the value is -0.72. The value appears to be declining and may need further review. It has decreased from -0.62 (Sep 2024) to -0.72, marking a decrease of 0.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:24 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: January 13, 2025, 2:32 pm

Below is a detailed analysis of the balance sheet data for Vivimed Labs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2024, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 17.00 Cr..
• For Reserves, as of Sep 2024, the value is -42.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -22.00 Cr. (Mar 2024) to -42.00 Cr., marking a decline of 20.00 Cr..
• For Borrowings, as of Sep 2024, the value is 376.00 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 377.00 Cr. (Mar 2024) to 376.00 Cr., marking a decrease of 1.00 Cr..
• For Other Liabilities, as of Sep 2024, the value is 593.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 579.00 Cr. (Mar 2024) to 593.00 Cr., marking an increase of 14.00 Cr..
• For Total Liabilities, as of Sep 2024, the value is 943.00 Cr.. The value appears to be improving (decreasing). It has decreased from 950.00 Cr. (Mar 2024) to 943.00 Cr., marking a decrease of 7.00 Cr..
• For Fixed Assets, as of Sep 2024, the value is 411.00 Cr.. The value appears to be declining and may need further review. It has decreased from 418.00 Cr. (Mar 2024) to 411.00 Cr., marking a decrease of 7.00 Cr..
• For CWIP, as of Sep 2024, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 23.00 Cr., marking an increase of 2.00 Cr..
• For Investments, as of Sep 2024, the value is 168.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 168.00 Cr..
• For Other Assets, as of Sep 2024, the value is 340.00 Cr.. The value appears to be declining and may need further review. It has decreased from 343.00 Cr. (Mar 2024) to 340.00 Cr., marking a decrease of 3.00 Cr..
• For Total Assets, as of Sep 2024, the value is 943.00 Cr.. The value appears to be declining and may need further review. It has decreased from 950.00 Cr. (Mar 2024) to 943.00 Cr., marking a decrease of 7.00 Cr..

However, the Borrowings (376.00 Cr.) are higher than the Reserves (₹-42.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Vivimed Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 23, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 22) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 5. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
• For Diluted EPS (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 5. It has decreased from -7.92 (Mar 22) to -39.62, marking a decrease of 31.70.
• For Cash EPS (Rs.), as of Mar 23, the value is -26.55. This value is below the healthy minimum of 3. It has decreased from -5.95 (Mar 22) to -26.55, marking a decrease of 20.60.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 0.17. It has decreased from 39.35 (Mar 22) to 0.17, marking a decrease of 39.18.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 4.75. It has decreased from 43.93 (Mar 22) to 4.75, marking a decrease of 39.18.
• For Revenue From Operations / Share (Rs.), as of Mar 23, the value is 22.57. It has decreased from 28.62 (Mar 22) to 22.57, marking a decrease of 6.05.
• For PBDIT / Share (Rs.), as of Mar 23, the value is -22.47. This value is below the healthy minimum of 2. It has decreased from -0.81 (Mar 22) to -22.47, marking a decrease of 21.66.
• For PBIT / Share (Rs.), as of Mar 23, the value is -35.55. This value is below the healthy minimum of 0. It has decreased from -3.02 (Mar 22) to -35.55, marking a decrease of 32.53.
• For PBT / Share (Rs.), as of Mar 23, the value is -39.88. This value is below the healthy minimum of 0. It has decreased from -7.82 (Mar 22) to -39.88, marking a decrease of 32.06.
• For Net Profit / Share (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 2. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
• For NP After MI And SOA / Share (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 2. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
• For PBDIT Margin (%), as of Mar 23, the value is -99.59. This value is below the healthy minimum of 10. It has decreased from -2.86 (Mar 22) to -99.59, marking a decrease of 96.73.
• For PBIT Margin (%), as of Mar 23, the value is -157.53. This value is below the healthy minimum of 10. It has decreased from -10.56 (Mar 22) to -157.53, marking a decrease of 146.97.
• For PBT Margin (%), as of Mar 23, the value is -176.72. This value is below the healthy minimum of 10. It has decreased from -27.32 (Mar 22) to -176.72, marking a decrease of 149.40.
• For Net Profit Margin (%), as of Mar 23, the value is -175.59. This value is below the healthy minimum of 5. It has decreased from -28.50 (Mar 22) to -175.59, marking a decrease of 147.09.
• For NP After MI And SOA Margin (%), as of Mar 23, the value is -175.59. This value is below the healthy minimum of 8. It has decreased from -28.50 (Mar 22) to -175.59, marking a decrease of 147.09.
• For Return on Networth / Equity (%), as of Mar 23, the value is -23,087.35. This value is below the healthy minimum of 15. It has decreased from -20.73 (Mar 22) to -23,087.35, marking a decrease of 23,066.62.
• For Return on Capital Employeed (%), as of Mar 23, the value is -52.25. This value is below the healthy minimum of 10. It has decreased from -2.80 (Mar 22) to -52.25, marking a decrease of 49.45.
• For Return On Assets (%), as of Mar 23, the value is -33.24. This value is below the healthy minimum of 5. It has decreased from -5.34 (Mar 22) to -33.24, marking a decrease of 27.90.
• For Long Term Debt / Equity (X), as of Mar 23, the value is 43.79. This value exceeds the healthy maximum of 1. It has increased from 0.18 (Mar 22) to 43.79, marking an increase of 43.61.
• For Total Debt / Equity (X), as of Mar 23, the value is 266.03. This value exceeds the healthy maximum of 1. It has increased from 1.10 (Mar 22) to 266.03, marking an increase of 264.93.
• For Asset Turnover Ratio (%), as of Mar 23, the value is 0.16. It has decreased from 0.18 (Mar 22) to 0.16, marking a decrease of 0.02.
• For Current Ratio (X), as of Mar 23, the value is 0.78. This value is below the healthy minimum of 1.5. It has decreased from 1.36 (Mar 22) to 0.78, marking a decrease of 0.58.
• For Quick Ratio (X), as of Mar 23, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 22) to 0.59, marking a decrease of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 23, the value is 1.17. This value is below the healthy minimum of 4. It has increased from 0.57 (Mar 22) to 1.17, marking an increase of 0.60.
• For Dividend Payout Ratio (NP) (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 22) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 22) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 22) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 22) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 23, the value is -5.19. This value is below the healthy minimum of 3. It has decreased from -0.17 (Mar 22) to -5.19, marking a decrease of 5.02.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 23, the value is -8.15. This value is below the healthy minimum of 3. It has decreased from -0.70 (Mar 22) to -8.15, marking a decrease of 7.45.
• For Enterprise Value (Cr.), as of Mar 23, the value is 430.11. It has decreased from 471.51 (Mar 22) to 430.11, marking a decrease of 41.40.
• For EV / Net Operating Revenue (X), as of Mar 23, the value is 2.30. This value is within the healthy range. It has increased from 1.99 (Mar 22) to 2.30, marking an increase of 0.31.
• For EV / EBITDA (X), as of Mar 23, the value is -2.31. This value is below the healthy minimum of 5. It has increased from -69.44 (Mar 22) to -2.31, marking an increase of 67.13.
• For MarketCap / Net Operating Revenue (X), as of Mar 23, the value is 0.29. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 22) to 0.29, marking a decrease of 0.21.
• For Retention Ratios (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 22) which recorded 0.00.
• For Price / BV (X), as of Mar 23, the value is 38.87. This value exceeds the healthy maximum of 3. It has increased from 0.36 (Mar 22) to 38.87, marking an increase of 38.51.
• For Price / Net Operating Revenue (X), as of Mar 23, the value is 0.29. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 22) to 0.29, marking a decrease of 0.21.
• For EarningsYield, as of Mar 23, the value is -5.94. This value is below the healthy minimum of 5. It has decreased from -0.56 (Mar 22) to -5.94, marking a decrease of 5.38.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness